Bioventus
BVS
138 hedge funds and large institutions have $537M invested in Bioventus in 2024 Q3 according to their latest regulatory filings, with 50 funds opening new positions, 42 increasing their positions, 24 reducing their positions, and 15 closing their positions.
233% more first-time investments, than exits
New positions opened: 50 | Existing positions closed: 15
142% more capital invested
Capital invested by funds: $222M → $537M (+$315M)
75% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 24
34% more funds holding
Funds holding: 103 → 138 (+35)
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
8.37% more ownership
Funds ownership: 60.57% → 68.94% (+8.4%)
11% less call options, than puts
Call options by funds: $2.32M | Put options by funds: $2.6M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$7.24M |
| 2 |
RA
Royce & Associates
New York
|
+$6.03M |
| 3 |
Nuveen
Charlotte,
North Carolina
|
+$4.6M |
| 4 |
OAM
Ophir Asset Management
Sydney,
Australia
|
+$4.53M |
| 5 |
Morgan Stanley
New York
|
+$4.19M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$8.54M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$2.37M |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$1.8M |
| 4 |
Millennium Management
New York
|
-$1.02M |
| 5 |
Renaissance Technologies
New York
|
-$997K |
BVS Hedge Fund Activity: Q3 2024 in Review
138 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Bioventus (BVS) for Q3 2024, worth a combined $537M — up 142% from $222M a quarter earlier.
Buyers outnumbered sellers: 50 funds opened new BVS positions and 15 closed out — a net gain of 35 holders — while 42 added to existing stakes and 24 trimmed.
The largest buyer was Driehaus Capital Management, opening a new position worth an estimated $7.24M. The largest seller was Nantahala Capital Management, cutting an estimated $8.54M.
- 138 institutional investors held Bioventus (BVS) as of Q3 2024, up from 103 in Q2 2024.
- Funds reported $537M of Bioventus stock for Q3 2024, up 142% quarter-over-quarter.
- 50 funds opened new Bioventus positions in Q3 2024 and 15 closed out, a net change of +35 holders.
- The largest Bioventus buyer in Q3 2024 was Driehaus Capital Management, an estimated $7.24M added.
- The largest Bioventus seller in Q3 2024 was Nantahala Capital Management, an estimated $8.54M sold.
Based on aggregated 13F filings for Q3 2024.